2.31
Immunitybio Inc stock is traded at $2.31, with a volume of 9.52M.
It is up +3.12% in the last 24 hours and down -14.76% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.24
Open:
$2.24
24h Volume:
9.52M
Relative Volume:
1.09
Market Cap:
$2.18B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.3814
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-9.41%
1M Performance:
-14.76%
6M Performance:
-32.46%
1Y Performance:
-44.47%
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IBRX
Immunitybio Inc
|
2.31 | 2.30B | 1.31M | -597.65M | -425.62M | -0.97 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-06-25 | Initiated | H.C. Wainwright | Buy |
Jan-10-25 | Initiated | BTIG Research | Buy |
May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent
ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener
ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com
ImmunityBio Inc. Stock Flags Risk Zone in Volatility IndexJuly 2025 EndofMonth & Entry Point Confirmation Signals - sundaytimes.kr
ImmunityBio Wins U.K. Approval - Los Angeles Business Journal
Fibonacci Retracement Aligns with Support in ImmunityBio Inc.July 2025 News Drivers & Fast Momentum Entry Tips - newsimpact.co.kr
Published on: 2025-08-17 09:14:13 - metal.it
Heatmap Data Shows High Activity in ImmunityBio Inc. Sector2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - sundaytimes.kr
Is ImmunityBio Inc.’s growth already priced inMarket Performance Recap & AI Powered Market Trend Analysis - thegnnews.com
Is ImmunityBio Inc. a speculative investmentTrade Volume Report & Fast Gain Swing Alerts - sundaytimes.kr
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter - Oncodaily
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock a value trap2025 Valuation Update & Expert Verified Stock Movement Alerts - thegnnews.com
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - ADVFN Brasil
RSI + MACD Show Convergence for ImmunityBio Inc.2025 Price Targets & Growth Focused Stock Pick Reports - sundaytimes.kr
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment - TipRanks
ImmunityBio shares fall 1.95% intraday after Q2 net loss and revenue rise. - AInvest
Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials - simplywall.st
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - BioSpace
ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential. - AInvest
ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener
Hillenbrand, ImmunityBio, V2X - TradingView
ImmunityBio Surges 15% on Groundbreaking Cancer Trial Results: A New Era for NK Cell Therapy? - AInvest
ImmunityBio announces early findings from QUILT-106 trial - TipRanks
ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade
Lumentum Holdings, ImmunityBio, V2X - TradingView
ImmunityBio Stock Surges on Robust Q2 Earnings Report - timothysykes.com
Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada
ImmunityBio's NK cell therapy shows promise in lymphoma trial. - AInvest
ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio rises after early data for blood cancer cell therapy - TradingView
ImmunityBio’s Stock Surges on Promising Trial Results - TipRanks
CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada
VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Vax-Before-Travel
ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - MarketScreener
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail
ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest
ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest
ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest
ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest
ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):